BR112013012504A2 - método para o tratamento de condições neurológicas com extrato de espécie nerium ou da espécie thevetia - Google Patents
método para o tratamento de condições neurológicas com extrato de espécie nerium ou da espécie thevetiaInfo
- Publication number
- BR112013012504A2 BR112013012504A2 BR112013012504A BR112013012504A BR112013012504A2 BR 112013012504 A2 BR112013012504 A2 BR 112013012504A2 BR 112013012504 A BR112013012504 A BR 112013012504A BR 112013012504 A BR112013012504 A BR 112013012504A BR 112013012504 A2 BR112013012504 A2 BR 112013012504A2
- Authority
- BR
- Brazil
- Prior art keywords
- nerium
- treatment
- neurological conditions
- species extract
- thevetia species
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41594510P | 2010-11-22 | 2010-11-22 | |
US12/987,693 US8481086B2 (en) | 2010-01-11 | 2011-01-10 | Method of treating neurological conditions with cardiac glycoside |
PCT/US2011/020672 WO2011085307A1 (en) | 2010-01-11 | 2011-01-10 | Method of treating neurological conditions with cardiac glycosides |
PCT/US2011/059090 WO2012071152A2 (en) | 2010-11-22 | 2011-11-03 | Method of treating neurological conditions with extract of nerium species or thevetia species |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013012504A2 true BR112013012504A2 (pt) | 2017-06-27 |
Family
ID=46146352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013012504A BR112013012504A2 (pt) | 2010-11-22 | 2011-11-03 | método para o tratamento de condições neurológicas com extrato de espécie nerium ou da espécie thevetia |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP2642859B1 (pt) |
JP (3) | JP6453538B2 (pt) |
KR (2) | KR101742852B1 (pt) |
CN (2) | CN103429251B (pt) |
AU (1) | AU2011332248B2 (pt) |
BR (1) | BR112013012504A2 (pt) |
CA (1) | CA2818601C (pt) |
ES (1) | ES2546518T3 (pt) |
HK (2) | HK1189764A1 (pt) |
MX (1) | MX345675B (pt) |
RU (1) | RU2606594C2 (pt) |
WO (1) | WO2012071152A2 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140066488A1 (en) * | 2012-08-30 | 2014-03-06 | Purdue Research Foundation | Inhibitors of Memapsin 2 Cleavage for the Treatment of Alzheimer's Disease |
EP2996684A4 (en) * | 2013-03-15 | 2016-11-30 | Univ Iowa Res Found | THERAPEUTIC PROCEDURES |
CN104914193B (zh) * | 2015-06-29 | 2016-08-10 | 公安部物证鉴定中心 | 生物样品中夹竹桃苷和夹竹桃苷乙的液相色谱-串联质谱检验方法 |
CN105878316A (zh) * | 2016-04-11 | 2016-08-24 | 天津中医药大学 | 黄花夹竹桃叶中总强心苷的提取方法及含量测定方法 |
AU2018334467B2 (en) * | 2017-09-14 | 2022-10-20 | Phoenix Biotechnology, Inc. | Method and improved neuroprotective composition for treating neurological conditions |
US20220031787A1 (en) | 2018-11-13 | 2022-02-03 | Green Tech Co., Ltd. | Agent for preventing and/or treating neurodegenerative diseases |
CN110487934A (zh) * | 2019-08-30 | 2019-11-22 | 浙江工业大学 | 齐墩果酸和熊果酸的分析方法 |
CN111494390B (zh) * | 2020-05-18 | 2022-08-19 | 南通大学 | 白桦醇衍生物在制备修复神经损伤药物中的新用途 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5236132A (en) | 1992-01-03 | 1993-08-17 | Vortec, Inc. | Gradient-force comminuter/dehydrator apparatus and method |
US5598979A (en) | 1995-04-20 | 1997-02-04 | Vortec, Inc. | Closed loop gradient force comminuting and dehydrating system |
JP2000247993A (ja) * | 1999-03-01 | 2000-09-12 | Toray Ind Inc | トリテルペノイド系化合物を含んでなるσレセプター作用薬 |
CN1129613C (zh) * | 1999-12-24 | 2003-12-03 | 中国科学院上海药物研究所 | 夹竹桃花多糖及其制备方法和应用 |
US6517015B2 (en) | 2000-03-21 | 2003-02-11 | Frank F. Rowley, Jr. | Two-stage comminuting and dehydrating system and method |
JP2002078468A (ja) * | 2000-09-06 | 2002-03-19 | Takenori Kato | 耐熱性金属イオンゲル入り飲料 |
US6715705B2 (en) | 2001-03-16 | 2004-04-06 | Frank F. Rowley, Jr. | Two-stage comminuting and dehydrating system and method |
US20040082521A1 (en) | 2002-03-29 | 2004-04-29 | Azaya Therapeutics Inc. | Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases |
EP1513403B1 (en) | 2002-05-28 | 2017-02-15 | Bette Pollard | Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders |
AU2003287526A1 (en) | 2002-11-06 | 2004-06-03 | Protein-stabilized liposomal formulations of pharmaceutical agents | |
WO2004087121A2 (en) | 2003-03-28 | 2004-10-14 | Azaya Therapeutics, Inc. | Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases |
PL1694320T3 (pl) * | 2003-12-19 | 2008-11-28 | Lipid Nutrition Bv | Zastosowanie kompozycji zawierających kwas oleanolowy i kwas ursolowy do wytwarzania leku do leczenia nadwrażliwości i nadreaktywności |
US7529217B2 (en) * | 2004-03-27 | 2009-05-05 | Dust Networks, Inc. | Low-power autonomous node for mesh communication network |
EP1812010A2 (en) | 2004-10-18 | 2007-08-01 | BTG International Limited | Use of na+/ k+-atpase inhibitors and antagonists thereof |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
KR101556805B1 (ko) * | 2007-11-13 | 2015-10-01 | 피닉스 바이오테크놀러지 인코포레이티드. | 강심배당체를 사용한 암 화학요법에서 치료 반응의 확률을 측정하는 방법 |
WO2009118411A2 (en) * | 2008-03-28 | 2009-10-01 | Nerviano Medical Sciences S.R.L. | 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
ES2326065B1 (es) * | 2008-03-28 | 2010-07-08 | Consejo Superior De Investigaciones Cientificas (Csic) | Utilizacion de un triterpeno pentaciclico para la preparacion de una composicion farmaceutica destinada al tratamiento de la esclerosis multiple. |
EP2523563B1 (en) * | 2010-01-11 | 2017-06-21 | Phoenix Biotechnology Inc. | Method of treating neurological conditions with cardiac glycosides |
-
2011
- 2011-11-03 KR KR1020137015981A patent/KR101742852B1/ko active IP Right Grant
- 2011-11-03 BR BR112013012504A patent/BR112013012504A2/pt not_active Application Discontinuation
- 2011-11-03 WO PCT/US2011/059090 patent/WO2012071152A2/en active Application Filing
- 2011-11-03 JP JP2013539875A patent/JP6453538B2/ja active Active
- 2011-11-03 CN CN201180065127.6A patent/CN103429251B/zh active Active
- 2011-11-03 ES ES11843119.6T patent/ES2546518T3/es active Active
- 2011-11-03 CA CA2818601A patent/CA2818601C/en active Active
- 2011-11-03 RU RU2013128609A patent/RU2606594C2/ru active
- 2011-11-03 AU AU2011332248A patent/AU2011332248B2/en active Active
- 2011-11-03 MX MX2013005739A patent/MX345675B/es active IP Right Grant
- 2011-11-03 CN CN201710431154.XA patent/CN107412775B/zh active Active
- 2011-11-03 KR KR1020177011219A patent/KR20170049623A/ko not_active Application Discontinuation
- 2011-11-03 EP EP11843119.6A patent/EP2642859B1/en active Active
-
2014
- 2014-04-01 HK HK14103098.9A patent/HK1189764A1/xx unknown
-
2016
- 2016-02-24 JP JP2016033219A patent/JP6453791B2/ja active Active
-
2017
- 2017-02-17 JP JP2017027479A patent/JP2017114888A/ja active Pending
-
2018
- 2018-05-24 HK HK18106778.5A patent/HK1247112A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP6453791B2 (ja) | 2019-01-16 |
JP2017114888A (ja) | 2017-06-29 |
AU2011332248B2 (en) | 2015-08-13 |
MX2013005739A (es) | 2014-02-03 |
CA2818601A1 (en) | 2012-05-31 |
KR20140005903A (ko) | 2014-01-15 |
JP6453538B2 (ja) | 2019-01-16 |
EP2642859B1 (en) | 2015-08-12 |
RU2013128609A (ru) | 2014-12-27 |
AU2011332248A1 (en) | 2013-06-13 |
WO2012071152A2 (en) | 2012-05-31 |
EP2642859A4 (en) | 2014-05-28 |
JP2013542988A (ja) | 2013-11-28 |
CA2818601C (en) | 2022-03-29 |
CN103429251B (zh) | 2017-09-15 |
CN107412775B (zh) | 2021-01-05 |
JP2016145223A (ja) | 2016-08-12 |
RU2606594C2 (ru) | 2017-01-10 |
MX345675B (es) | 2017-02-10 |
KR20170049623A (ko) | 2017-05-10 |
HK1247112A1 (zh) | 2018-09-21 |
KR101742852B1 (ko) | 2017-06-15 |
CN107412775A (zh) | 2017-12-01 |
ES2546518T3 (es) | 2015-09-24 |
WO2012071152A4 (en) | 2012-08-16 |
HK1189764A1 (en) | 2014-06-20 |
EP2642859A2 (en) | 2013-10-02 |
CN103429251A (zh) | 2013-12-04 |
WO2012071152A3 (en) | 2012-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012018943A8 (pt) | medicamento e método para o tratamento e/ou prevenção de um câncer | |
BR112013012504A2 (pt) | método para o tratamento de condições neurológicas com extrato de espécie nerium ou da espécie thevetia | |
BR112015001032A2 (pt) | método para tratamento de plantas de tabaco com enzimas | |
BR112013007678A2 (pt) | método para tratamento de doenças alérgicas | |
BR112014032105A2 (pt) | método para o tratamento de câncer | |
BR112014031806A2 (pt) | método para tratamento de câncer positivo para gd2 | |
EP2830637A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES RELATED TO OXIDATIVE STRESS | |
BR112013008957A2 (pt) | composições e métodos para tratamento de doenças endócrinas, gastrointestinais ou autoimunes | |
BR112014013843A2 (pt) | uso de dispositivos para o tratamento de doenças neurológicas | |
BR112012004836A2 (pt) | pirazinilpiridinas úteis para o tratamento de doenças proliferativas | |
BR112013016491A2 (pt) | método para tratamento de têxtil | |
ZA201402450B (en) | Method for the fungicidal and /or bactericidal treatment of resistant strains using one or more essential oils | |
BR112014009785A2 (pt) | método para tratar ou reduzir efp | |
HK1215173A1 (zh) | 治療金黃色葡萄球菌相關疾病的方法 | |
BR112013011659A2 (pt) | métodos de tratamento do câncer | |
ZA201208172B (en) | Methods for the treatment of il-1b related conditions | |
BR112012000095A2 (pt) | método de tratamento ou prevenção de ponv ou pdnv | |
HK1208503A1 (en) | Euglobulin-based method for determining the biological activity of defibrotide | |
EP2685997A4 (en) | COMPOSITION CONTAINING EXTRACT FROM A COMBINATION OF HERBS USEFUL FOR THE PREVENTION OR TREATMENT OF PERIPHERAL DIABETIC NEUROPATHY | |
BR112015011192A2 (pt) | método para tratamento de águas residuais e usina para tratamento de águas residuais | |
BR112015008798A2 (pt) | método para o tratamento de plantas e uso | |
HK1210163A1 (en) | Compositions and methods for treating or preventing pneumovirus infection and associated diseases | |
IL229705A0 (en) | Methods for the treatment or prevention of neurological diseases | |
EP2941255A4 (en) | METHOD FOR TREATING OR RELIEVING A DISEASE CAUSED OR AGGRAVATED BY MICROORGANISMS | |
EP2832376A4 (en) | METHOD FOR TREATING A BIOLOGICAL TISSUE AND BIOLOGICAL TISSUE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |